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1040-67 The Impact of the National Privacy Act on the 
Effectiveness and Costs of a Six-Month Follow-Up 
Study of Acute Coronary Syndromes
David Armstrong, Eva M. Kline-Rogers, Jianming Fang, Anchal Sud, Krishna Rangarjan, 
Shaneen U. Doctor, Bruce C. Rogers, Debra Smith, Kim A. Eagle, University of Michigan, 
Ann Arbor, MI
Objective: To determine the potential impact of the new privacy act (HIPAA) on post dis-
charge outcomes (effectiveness and costs) in patients with Acute Coronary Syndromes
(ACS).
Methods: We studied follow-up(F/U) success at 6 months, and costs of F/U in two
cohorts of consecutive discharges with ACS between 5-1-99 and 4-24-03 at the Univer-
sity of Michigan Health System. The first interval represented usual outcomes assess-
ment, with 6 month phone interviews which first sought verbal consent from patients,
then proceeded with a brief questionnaire. In the second interval, using methodology rec-
ommended by our IRB as being HIPAA compliant, we first mailed a consent to each dis-
charged patient, asking permission to call the patient in order to add their clinical data to
a database and obtain F/U information. We tracked overall success of consent for 6
month F/U, incremental costs of securing F/U, including estimated materials, mailing,
phone, personnel costs, and assessed for differences in types of patients successfully
consented.
Results: Overall consent for F/U dropped from 96.5 % to 35.9% after initiation of HIPAA
compliant procedures, p<.0001. Per patient costs increased by an estimated $17.00.
More than one half of patients did not reply to the consent letter. After receiving the letter,
2.6% of patients refused to be contacted and 1.5% of letters were "returned to sender".
Patients successfully consented for F/U after HIPAA were more likely to be married
(p<.0001), were older (p=.001) and have a history of hypertension (p=.004) or hyperlipi-
demia (p=.04) versus those that did not respond, refused, or never received the letter.
Widowers were less likely to respond (p<.0001). There were no differences with regard to
gender, or other comorbid conditions between those that did or did not consent.
Conclusions: Adjusting outcomes research methodology to accomodate new regulations
associated with HIPAA resulted in substantial reduction in our ability to successfully track
care patterns and outcomes in pts discharged after admission for ACS, and was associ-
ated with greater costs. This pilot study suggests that HIPAA may significantly alter the
way we study long term patient outcomes in cardiology.
1040-68 Excessive Inducement Into Clinical Trials Using 
Monetary Incentives: Truth or Fallacy?
Joel B. Braunstein, Steven P. Schulman, Parthiv Mahadevia, Neil R. Powe, Johns 
Hopkins Medical Institutions, Baltimore, MD
Background: While use of monetary incentives to enhance recruitment into clinical trials
is controversial, scant empiric data exist on how monetary incentives actually influence
patients’ enrollment decisions. Thus, we asked whether and to what degree monetary
incentives influence patients’ willingness to participate (WTP) in a cardiovascular clinical
trial.
Methods: From 13 Maryland-based cardiology and medicine clinics, we approached
1440 randomly selected patients to participate in a cross-sectional, self-administered
survey, which contained a 1-page description of a cardiovascular drug trial with random
assignment of a different level of monetary incentive. Monetary incentive for joining ran-
domly varied between $25, $250, $500, $750, and $1250. Using 5-point Likert response
scaling, patients reported their WTP ([+] response = very likely/ likely), and their rated
importance of joining a trial for altruistic reasons and for receiving monetary incentive.
Results: 789 (70%) of 1132 eligible individuals responded. Magnitude of monetary
incentive had no impact on WTP (WTP=32%, 36%, 34%, 33%, 38% for $25, $250, $500,
$750 and $1250 incentive, respectively, p=0.80), even after stratifying individuals by
socioeconomic status, age, gender, and race. Individuals who considered monetary
incentive important to join a trial, however, expressed greater WTP (OR=1.24; 95% CI
1.11-1.38, p<0.001 per ordered increase in importance), as did individuals who consid-
ered it important to join a trial to help other people (2.32; 1.92-2.81, p<0.001 per ordered
increase in importance). Lower income and education levels were both strongly and inde-
pendently associated (1.33; 1.08-1.63, p<0.01 and 1.65; 1.26-2.16, p<0.001 per ordered
decrease in income and education, respectively) with reports of monetary incentive being
either extremely or very important to joining a trial. All subgroups felt similarly about the
importance of joining a trial to help other people.
Conclusions: Monetary incentives did not adversely influence WTP in this hypothetical
experiment, although, persons with lower income and education were more likely to
believe that monetary incentives are important for joining trials.
1040-69 The Effect of State Mandated Continuing Medical 
Education on the Use of Proven Therapies in Patients 
With an Acute Myocardial Infarction
Manesh R. Patel, Trip J. Meine, Jasmina Radeva, Lesley Curtis, Sunil V. Rao, Kevin J. 
Schulman, James Jollis, Duke University Medical Center, Durham, NC
Background: Many states mandate continuing medical education (CME) credits for
practicing physicians. We examined whether state CME requirements affected the use of
evidence-based therapies and outcomes in patients with acute myocardial infarction
(AMI).
Methods: We analyzed 134,609 patients in a Medicare database admitted with the diag-
nosis of AMI to US hospitals from 1994-1996 according to CME requirements in the state
of physician practice. We used a hierarchical multivariable model controlling for state,
hospital, physician, and patient characteristics to determine the association between
state CME requirements and the use of evidence-based therapies.
Results: States with and without CME requirements had similar rates of aspirin use at
admission and discharge and beta blocker use at discharge. The rate of reperfusion ther-
apy at admission was significantly higher in states requiring CME.(Table) After adjust-
ment, patients admitted in states requiring CME were significantly more likely to receive
reperfusion therapy, mainly due to thrombolytic therapy (RR 1.08 p=0.023). There was no
association between CME requirements and 30-day or 1-year mortality.
Conclusion: State-mandated CME training had little association with AMI care or out-
come, other than an increased use of thrombolytic therapy. Further study is needed to
determine whether the association with thrombolysis was related to the provision of CME
activities in conjunction with pharmaceutical marketing efforts.
1040-70 Do International Medical Graduates Provide Inferior 
Quality Care in the Setting of Acute Myocardial 
Infarction?
Dennis T. Ko, Peter C. Austin, Benjamin T.B. Chan, Jack V. Tu, Sunnybrook and Women’s 
College Health Sciences Center, Toronto, ON, Canada, Institute for Clinical Evaluative 
Sciences, Toronto, ON, Canada
Background
International medical graduates (IMGs) represent a substantial proportion of the physi-
cian workforce and are important in the care of AMI patients. Although not firmly estab-
lished, many believe that IMGs provide inferior medical care compared to locally trained
physicians.
Methods 
We compared risk-adjusted mortality rates, adjusted use of secondary prevention medi-
cations and cardiac procedures of patients treated by IMGs and Canadian Medical grad-
uates (CMGs) using linked administrative databases for all patients admitted with AMI
between 1992 and 1999 in Ontario, Canada.
Results
Of the 127,275 AMI patients, 22% were treated by IMGs, and 78% by CMGs. IMGs were
older (51 vs 40 yrs) and more likely to be male (90% vs 72%) compared to CMGs. The
risk-adjusted mortality rates of IMG and CMG-treated patients were similar both at 30-
day (13.3% vs 13.4%, p = 0.57) and at 1-year (21.8% vs 21.9%, p = 0.63). Further,
patients treated by both groups had similar adjusted utilization of secondary prevention
medications and cardiac procedures.
Conclusions
Despite concerns about a lower level of care provided by IMGs, the utilization of second-
ary prevention medical therapy, cardiac procedures, and mortality of AMI patients was
similar after adjustment. This information places the concerns about IMGs into perspec-
tive and supports the ability of well-selected IMGs in caring for AMI patients. 
Use of Evidence-Based Therapy in AMI
States with no CME-
requirement N=63,299
CME-requiring 
States N=71,310
P-Value
Aspirin:
During 79.4% 79.9% 0.088
at discharge 72.5% 72.5% 0.947
Beta-Blocker use
 During 63.3% 61.6% 0.045
 Discharge 55.3% 53.1% 0.068
Reperfusion at 
Admission
 PCI 18.6% 20.9% 0.0007
Thrombolytic 42.6% 47.2% <0.0001
Mortality
 30-day 20.5% 20.7% 0.467
 1-year 35.2% 35.0 0.564
